Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.
OBJECTIVE
To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch. Repeat comparison for the subset of patients treated in long-term care (LTC) settings.


METHODS
Patients, age≥18 years, with PHN diagnosis, or PHN-likely patients with herpes zoster diagnosis and ≥30 days of PHN-recommended treatment, were identified in Medicaid claims from Florida, Iowa, Missouri, and New Jersey (1999-2007). Patients had continuous eligibility 6 months before (baseline) and 12 months after (study period) the PHN index date. Patients with ≥1 claim for a lidocaine patch during the study period (n=872) were compared to patients without a lidocaine patch claim (comparison group). Baseline characteristics, study period treatment and healthcare costs (reimbursements by Medicaid for medical services and prescription drugs) were compared between groups using univariate analyses.


RESULTS
PHN patients in the lidocaine patch group were older (64.5 vs. 62.2 years; p=0.002) and had higher rates of pain-related comorbidities (e.g., back/neck pain, osteoarthritis) than comparison patients. Average PHN-related drug costs per patient were higher ($1994 vs. 1137; p<0.0001) among lidocaine patch patients, with lidocaine patch accounting for $505 of the difference. PHN-related medical costs appeared lower in the lidocaine patch group, although not statistically significant ($983 vs. 1294; p=0.1348). No significant differences were found in total healthcare costs ($20,175 vs. 19,124; p=0.3720) across groups, despite higher total prescription drug costs among lidocaine patch patients. A similar pattern was observed among LTC patients.


CONCLUSIONS
Despite higher rates of comorbidities and prescription drug costs, lidocaine patch patients had similar study period healthcare costs as comparison patients. The cost of the lidocaine patch represented a small fraction of overall costs incurred over the study period.


CONCLUSIONS
Findings are based on a Medicaid sample and may not be generalizable to all PHN patients.
Kirson
Noam Y
NY
Analysis Group, Inc., Boston, MA 02199, USA. nkirson@analysisgroup.com
Ivanova
Jasmina I
JI
Birnbaum
Howard G
HG
Wei
Robert
R
Kantor
Evan
E
Amy Puenpatom
R
R
Ben-Joseph
Rami H
RH
Summers
Kent H
KH
D000368:Aged; D000704:Analysis of Variance; D000779:Anesthetics, Local / Q000008:administration & dosage* / Q000191:economics*; D015897:Comorbidity; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007345:Insurance Claim Review; D008012:Lidocaine / Q000008:administration & dosage* / Q000191:economics*; D008297:Male; D008484:Medicaid / Q000191:economics / Q000706:statistics & numerical data; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000188:drug therapy* / Q000191:economics*; D057968:Transdermal Patch; D014481:United States
D000779:Anesthetics, Local; D008012:Lidocaine